iCS-digital TM PSC: a long-standing track record
Ncardia has been one of Stem Genomics’ first clients. They started using our tests a few weeks after we launched our company back in 2018. Service supplier of Ncardia Belgium at first, then Ncardia Netherlands, we continue to support this client in the work they do with hiPSCs nowadays. They particularly appreciate our fast lead time and the smooth communication that has been established between us.
What type of work does Ncardia actually do with hiPSCs ?
Through their hiPSC platform, Ncardia provides a comprehensive menu of cardiovascular and neuronal services for drug discovery. These services start with the generation and differentiation of hiPSCs. They use their own hiPSC lines to generate cell types such as cardiomyocytes, epithelial cells, stromal or neurons, but they can also work from client’s cell lines. This process requires regular monitoring of the hiPSCs.
Why hiPSC genetic analysis matter for them ?
Generation and differentiation of cells both cause stress to the cells in culture. This can consequently lead to abnormalities that can create issues down the line for research scientists. Therefore, cell characterisation is crucial in the manufacturing process. Ncardia has put a stringent quality control process in place to ensure the hiPSC lines they produce remain of high quality throughout the culture process.
Why use Stem Genomics’ assays ?
Arie Reijerkerk, Director Manufacturing Technology at Ncardia, likes the fact that “the results are obtained very quickly and the reports are clearly interpreted. There is also a smooth line of communication between Ncardia and Stem Genomics whenever we require further clarifications. When we have a question, we get a clear answer, usually the same day. This naturally brings us the reassurance we are after”.
Ncardia is one of the leading hiPSC (Human Induced Pluripotent Stem Cells) technology companies worldwide. With over 15 years’ experience, their mission is to enable biopharmaceutical companies in drug discovery and cell therapy to bring better therapies to patients faster, by integrating human iPSC technologies in their development process. Their expertise coupled with their high-quality standards have made Ncardia a best-in-class organisation on the hiPSC market.